Panel Will Weigh Overton’s FDA Public-Health Direction

Why it Matters

The Senate will examine Heidi Overton's nomination to lead the Food and Drug Administration on [September 24 (https://app.legis1.com/hearings/detail?id=31650#summary), as the agency faces scrutiny over food safety, drug approvals, and public health priorities under the incoming administration. Overton, from New Mexico, would oversee an agency managing everything from pharmaceutical approvals to dietary supplements at a moment when Congress and the administration are signaling appetite for regulatory changes. The confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions will test whether Overton's record and views align with the committee's priorities on drug pricing, food safety modernization, and the role of federal health regulators.

The hearing will be chaired by Sen. Bill Cassidy (R-LA), with Sen. Bernie Sanders (I-VT) as ranking member.

Broader Context

Recent congressional activity signals heightened focus on FDA operations and food and drug policy more broadly, with members from New Mexico pressing federal agencies on overlapping health and safety matters. In September, a New Mexico delegation called on the Department of Justice inspector general to expand an investigation into DEA fentanyl practices in the state, and pressed the Veterans Affairs secretary to protect New Mexico veterans from potential harm during agency reorganization. Rep. Gabe Vasquez (D-NM) separately demanded that HHS Secretary Kennedy protect Head Start programs for New Mexico children, signaling concern over changes to health and human services delivery in the state.